GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » Price-to-Owner-Earnings

CHRO (Chromocell Therapeutics) Price-to-Owner-Earnings : (As of Sep. 24, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics Price-to-Owner-Earnings?

As of today (2024-09-24), Chromocell Therapeutics's share price is $0.80. Chromocell Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Chromocell Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


CHRO's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.525
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-09-24), Chromocell Therapeutics's share price is $0.80. Chromocell Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-1.81. Therefore, Chromocell Therapeutics's PE Ratio for today is At Loss.

As of today (2024-09-24), Chromocell Therapeutics's share price is $0.80. Chromocell Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.81. Therefore, Chromocell Therapeutics's PE Ratio without NRI for today is At Loss.


Chromocell Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Chromocell Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics Price-to-Owner-Earnings Chart

Chromocell Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - -

Chromocell Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Chromocell Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Chromocell Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chromocell Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chromocell Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Chromocell Therapeutics's Price-to-Owner-Earnings falls into.



Chromocell Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Chromocell Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.80/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chromocell Therapeutics  (AMEX:CHRO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Chromocell Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Chromocell Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Chromocell Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.

Chromocell Therapeutics Headlines

From GuruFocus

Chromocell Announces Stock Repurchase Plan

By Marketwired 08-07-2024